Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
2.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
3.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Blood
; 141(5): 519-528, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36084320
4.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
5.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
6.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
7.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Blood
; 137(10): 1365-1376, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32992344
8.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
9.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
10.
DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.
Haematologica
; 106(8): 2066-2075, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32646889
11.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
12.
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Ann Hematol
; 100(8): 2043-2050, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33973053
13.
Mutations driving CLL and their evolution in progression and relapse.
Nature
; 526(7574): 525-30, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26466571
14.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1188-1200, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888452
15.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood
; 131(9): 955-962, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29255066
16.
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.
Int J Cancer
; 144(11): 2695-2706, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30447004
17.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(9): 1215-1228, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30115596
18.
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Blood
; 137(16): 2267-2271, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512465
19.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401022
20.
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
Blood
; 135(11): 866-870, 2020 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31990291